Latest Interferon beta-1a Stories
However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression,
~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and
ROCKLAND, Mass., Sept.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
ROCKLAND, Mass., May 28, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif(®) (interferon beta-1a) data will be presented at the 2014
- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated
- A transitional zone between two communities containing the characteristic species of each.